Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
2.401
-0.190 (-7.32%)
Mar 31, 2025, 1:15 PM EDT - Market open
Lipella Pharmaceuticals Revenue
Lipella Pharmaceuticals had revenue of $80.38K in the quarter ending September 30, 2024, a decrease of -22.75%. This brings the company's revenue in the last twelve months to $483.53K, up 0.78% year-over-year. In the year 2023, Lipella Pharmaceuticals had annual revenue of $449.62K with 144.15% growth.
Revenue (ttm)
$483.53K
Revenue Growth
+0.78%
P/S Ratio
5.06
Revenue / Employee
$76,622
Employees
7
Market Cap
2.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 449.62K | 265.46K | 144.15% |
| Dec 31, 2022 | 184.16K | -75.19K | -28.99% |
| Dec 31, 2021 | 259.35K | -702.34K | -73.03% |
| Dec 31, 2020 | 961.68K | 266.94K | 38.42% |
| Dec 31, 2019 | 694.75K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
LIPO News
- 23 days ago - Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewsWire
- 26 days ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - GlobeNewsWire
- 6 weeks ago - Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - Benzinga
- 7 weeks ago - Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus - GlobeNewsWire
- 2 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - GlobeNewsWire
- 3 months ago - Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - GlobeNewsWire
- 3 months ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - GlobeNewsWire
- 5 months ago - Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire